<DOC>
	<DOCNO>NCT00695188</DOCNO>
	<brief_summary>The primary objective determine whether erythrocyte polyglutamate level associate objective clinical response patient rheumatoid arthritis oral administration low-dose methotrexate.The secondary aim study compare efficacy safety standard dose methotrexate versus high start dose .</brief_summary>
	<brief_title>Methotrexate Polyglutamate Levels Marker Clinical Outcome Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description>The folate antagonist methotrexate ( MTX ) currently one widely use drug treatment rheumatoid arthritis ( RA ) .Although MTX effective well tolerated , major drawback large interpatient variability clinical response.MTX intracellularly convert folylpolyglutamate synthetase ( FPGS ) methotrexate polyglutamates ( MTXPGs ) , enhance intracellular retention MTX . Furthermore , Î³-linked sequential addition glutamic acid residue inhibit final step de novo purine pyrimidine biosynthesis , result anti-proliferative anti-inflammatory effects.76 adult , MTX-naive patient fulfill American College Rheumatology criterion ( ACR ) RA Disease Activity Score 28 joint ( DAS-28 ) &gt; 3.2 enrol two site Vienna ( Austria ) .Clinical status assess number joint count Health Assessment Questionnaire ( HAQ ) .Patients randomly assign receive either standard dose high start dose 25 mg orally . In week 5 , subcutaneous dose 25 mg administer patient get reference level ( bioavailability 100 % ) .The patient participate 16 week , blood sample collect week 1 , 2 , 5 , 6 , 10 11 perform pharmacokinetic analysis metabolite measurements.The determination erythrocyte MTXPG-levels perform use HPLC technique.The primary outcome objective clinical response ( measure rheumatic score , DAS-28 ) , secondary outcome parameter quality life routine laboratory parameter use rheumatology . This clinical outcome correlate MTX pharmacokinetics blood , MTXPG kinetics erythrocytes , impact folate pathway .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>MTXnaive Age &gt; 18 year DAS28 &gt; 3.2 American College Rheumatologycriteria RA ChestXray Informed consent Prednisolon &lt; 10 mg day Pregnancy Lactation Renal hepatic impairment Malignant diseases ( last 5 year ) Contraindications Human Immunodeficiency Virus ( HIV ) , Hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>MTX polyglutamates</keyword>
	<keyword>clinical outcome</keyword>
</DOC>